cabiralizumab

Drug Overview

Cabiralizumab is an experimental cancer medication currently being studied in clinical research trials. It belongs to a cutting-edge class of cancer treatments known as Immunotherapy and Targeted Therapy.

Unlike traditional chemotherapy, which attacks all fast-growing cells in the body, cabiralizumab is a “Smart Drug” designed to change the environment around the tumor. It works by targeting specific immune cells that cancer uses to protect itself, aiming to strip away the tumor’s defenses so the body’s natural immune system can fight the disease. Because it is still being researched, it is not available at regular pharmacies and is only given to patients participating in approved clinical trials.

• Generic Name: Cabiralizumab (also known in research as FPA008)
• US Brand Names: None (Currently an Investigational Agent)
• Drug Class: CSF1R Inhibitor / Monoclonal Antibody
• Route of Administration: Intravenous (IV) Infusion (delivered directly into a vein)
• FDA Approval Status: Not FDA Approved. It is strictly an investigational drug used in clinical research.

What Is It and How Does It Work? (Mechanism of Action)

Cabiralizumab is a Targeted Immunotherapy made from a specialized, laboratory-created protein called a monoclonal antibody. Its main goal is to stop cancer cells from brainwashing the body’s immune system.

To understand how it works, we must look at special immune cells called macrophages. In a healthy body, macrophages are the “garbage collectors” and “guards” that eat dead cells and fight infections. However, tumors are very clever. They release chemicals that attract macrophages and brainwash them into becoming Tumor-Associated Macrophages (TAMs). Instead of fighting the cancer, these TAMs create a protective shield around the tumor, feeding it and stopping other cancer-killing immune cells (called T-cells) from attacking.

At the molecular level, cabiralizumab destroys this shield through a precise process:

1. Blocking the Antenna: The brainwashed TAMs have an antenna on their surface called CSF1R (Colony Stimulating Factor 1 Receptor). They need this antenna to receive survival signals (proteins called CSF-1 and IL-34).
2. Starving the TAMs: Cabiralizumab perfectly fits over the CSF1R antenna like a cap. Because the antenna is blocked, the TAMs can no longer receive their survival signals.
3. Removing the Shield: Without these signals, the protective TAMs stop working and die off. With the macrophage shield gone, the patient’s cancer-killing T-cells can finally flood into the tumor and destroy the cancer cells.

FDA Approved Clinical Indications

Because cabiralizumab is still an investigational medicine, it does not currently have any official FDA-approved uses for the general public.

Oncological Uses (Investigational)

Researchers are currently studying cabiralizumab for the following cancers, usually in combination with other immunotherapy drugs (like nivolumab):

• Advanced Pancreatic Cancer.
• Advanced Melanoma (skin cancer) that has stopped responding to other treatments.
• Renal Cell Carcinoma (Kidney cancer).
• Non-Small Cell Lung Cancer (NSCLC).
• Triple-Negative Breast Cancer.
• Tenosynovial Giant Cell Tumor (TGCT) / Pigmented Villonodular Synovitis (PVNS), a rare tumor of the joints.

Non-Oncological Uses (Investigational)

• Historically explored in early trials for autoimmune diseases like Rheumatoid Arthritis, because blocking macrophages can also reduce severe joint inflammation.

Dosage and Administration Protocols

Because cabiralizumab is an experimental drug, there is no single, commercially available dosage. The exact amount a patient receives is strictly determined by the rules of their specific clinical trial protocol.

• 
  Renal and Hepatic Insufficiency: Because this is an experimental drug, precise dose adjustments for patients with kidney (renal) or liver (hepatic) disease are not completely established. During trials, patients who develop sudden spikes in liver enzymes have their doses temporarily paused or reduced to ensure their organs remain safe.

Clinical Efficacy and Research Results

Clinical research data (spanning 2020 to 2025) has shown that while the science behind cabiralizumab is highly advanced, dealing with the immune system is very complex.

• Pancreatic Cancer Trials: A highly anticipated Phase 2 clinical trial testing cabiralizumab combined with nivolumab (Opdivo) for advanced pancreatic cancer did not meet its primary goals in 2020. The combination did not significantly improve Progression-Free Survival (the time the cancer is stopped from growing) compared to standard chemotherapy.
• Melanoma and Kidney Cancer: In recent studies (2023–2024), doctors have tried combining cabiralizumab with other immune boosters (like CD40 agonists). While some heavily pre-treated patients saw their disease stabilize (stop growing for a period of time), the overall tumor shrinkage rates (response rates) remained low.
• Current Research Focus: Scientists have learned from these numbers that “more is not always better.” Current studies are focusing on finding the exact right dose. Giving too much of the drug might accidentally cause the body to make new, different types of suppressive immune cells. Research continues to figure out exactly which patients will benefit the most.

Safety Profile and Side Effects

Like all immunotherapies that alter how the immune system behaves, cabiralizumab can cause side effects. Because it is an investigational drug, there is no formal FDA “Black Box Warning” at this time, but trial participants are monitored extremely closely.

Common Side Effects (>10%)

• Enzyme Elevations: The most common side effect is a painless but significant rise in blood enzymes, specifically liver enzymes (AST/ALT) and muscle enzymes (Creatine Kinase/CK).
• Periorbital Edema: Noticeable swelling and puffiness around the eyes.
• Fatigue: Feeling unusually tired or lacking energy.
• Skin Rash: Mild to moderate itching or redness on the skin.

Serious Adverse Events

• Myositis: Severe inflammation and pain in the muscles.
• Pneumonitis: Immune-related inflammation in the lungs, which can cause severe shortness of breath or acute respiratory distress.
• Severe Liver Toxicity: Dangerously high liver inflammation requiring immediate medical intervention.

Management Strategies

• Routine Blood Tests: Doctors will require frequent blood tests before every infusion to watch liver and muscle enzymes. If numbers get too high, the drug is skipped until the body recovers.
• Steroid Use: If the immune system becomes too aggressive and attacks healthy organs (like the lungs or liver), doctors will prescribe corticosteroid medicines (like prednisone) to calm the immune system down.

Connection to Stem Cell and Regenerative Medicine

Cabiralizumab is deeply connected to Stem Cell Research because of how immune cells are born. All macrophages in the body originally start as Hematopoietic Stem Cells (blood-forming stem cells) inside the bone marrow. By using cabiralizumab to block the CSF1R pathway, scientists are essentially studying how to send new instructions to the bone marrow. Current regenerative oncology research is exploring how we can use drugs like cabiralizumab to stop the bone marrow from creating “bad” tumor-protecting cells, and instead encourage the stem cells to regenerate only “good” healthy immune cells that fight disease.

Patient Management and Practical Recommendations

Pre-Treatment Tests to be Performed

Before joining a clinical trial for cabiralizumab, patients will undergo comprehensive testing:

• Comprehensive Metabolic Panel (CMP): To establish a baseline for liver function.
• Creatine Kinase (CK) Test: A blood test to check baseline muscle health.
• Tumor Biopsies: Doctors will often take a small sample of the tumor to measure exactly how many macrophages are currently inside it.

Precautions During Treatment

• Patients must be extremely vigilant about noticing new muscle aches, as this can be an early sign of muscle inflammation (myositis).
• Patients should monitor their breathing carefully and report any new, dry coughs to their trial doctor immediately.

“Do’s and Don’ts” list

• DO keep a daily symptom journal, noting any swelling around your eyes or sudden exhaustion, and share it with your trial nurse.
• DO tell all other doctors (including emergency room staff or dentists) that you are participating in an immunotherapy clinical trial.
• DON’T start any new exercise routines that are highly strenuous without asking your doctor, as your muscle enzymes may already be elevated from the drug.
• DON’T take any new over-the-counter herbal supplements or vitamins without clearing them with your oncology team, as they can interfere with liver tests.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Cabiralizumab is an investigational product and is not approved by the FDA for the treatment, cure, or prevention of any disease. Treatment protocols, dosages, and side effects vary by individual and by specific clinical trial guidelines. Patients should always consult with their primary oncologist or a qualified healthcare professional regarding diagnosis, clinical trial options, and the management of medical conditions. Do not disregard professional medical advice or delay in seeking it because of something you have read in this material.